NCT02826434View on ClinicalTrials.gov

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 18, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2027

Conditions
Breast Cancer
Interventions
BIOLOGICAL

PVX-410

This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.

BIOLOGICAL

Durvalumab

This is an intravenous infusion of a monoclonal antibody.

DRUG

Hiltonol

This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.

Trial Locations (5)

10016

New York University School of Medicine, New York

33607

Lee Moffitt Cancer Center and Research Institute, Tampa

02114

Massachusetts general Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

OncoPep, Inc.
AstraZeneca
All Listed Sponsors
collaborator

OncoPep, Inc.

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

Massachusetts General Hospital

OTHER